![](https://partners4access.com/wp-content/uploads/2020/07/France-ATU-jmage-3-1.jpeg)
France’s New ATU Process: Why only truly innovative therapies should now apply
By Nicola Allen, Associate Director & Andrea Bernardini, Analyst Email: [email protected] or [email protected] The French Authorisation for Temporary Use (ATU) was originally established in 1994
![](https://partners4access.com/wp-content/uploads/2020/11/India-Flag.png)
India’s new draft national policy for rare disease and the road to accessing gene therapies
By Ciaran Cassidy, Snr Analyst Email: [email protected] With one of the fastest-growing economies and the second largest population in the world India is a market
![](https://partners4access.com/wp-content/uploads/2020/11/shutterstock_661767619-scaled-1-768x405.jpeg)
4 key trends changing the access landscape through to 2025
By Jens Leutloff, Senior Consultant Email: [email protected] Partners4Access asked payer experts from France, Germany, Italy, Spain, and the Nordics what the key trends are for
![](https://partners4access.com/wp-content/uploads/2020/10/blog-post-image_oct-2020_CS-768x512.jpeg)
HTA and pricing update: Recent moves on drug cost-control by European payers
By Chloe Sheppard, Analyst Email: [email protected] The issue of affordability and access to medicines has been brought to the forefront of policymakers’ and payers’ attention
![](https://partners4access.com/wp-content/uploads/2020/09/Capitol-dome-with-flag.jpeg)
Trump finally signs executive order on Medicare drug pricing but will anything change on the ground?
By Max Rex, Consultant Email: [email protected] After years of rhetoric about drug pricing, President Trump signed an executive order on Sunday 13th September which aims
![](https://partners4access.com/wp-content/uploads/2020/09/WODC-US-2020-logo-_2.png)
Driving patient access for treatments targeting rare genetic disorders in the Middle East
By Ciaran Cassidy, S Analyst Email: [email protected] At the World Orphan Drug Conference (WODC) this year Dr Maryam Matar presented on the success of the
![](https://partners4access.com/wp-content/uploads/2020/08/European-Commission-Image-768x512.jpeg)
Under the microscope: Orphan Drug incentives in Europe
By Chloe Sheppard, Analyst Email: [email protected] The European Commission is imminently expected to publish a report evaluating the pros and cons of the EU Orphan
![](https://partners4access.com/wp-content/uploads/2020/07/France-ATU-jmage-3-1.jpeg)
France to place restrictions on Nominative ATU
By Erfan Akbraian, Analyst Email: [email protected] France’s National Agency for the Safety of Medicines and Health Products (ANSM)1 governs the early access program called autorisation
![](https://partners4access.com/wp-content/uploads/2020/05/syringe-1884784_1920-768x461.jpeg)
Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?
By Max Rex, Associate Consultant Email: [email protected] Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green